Articles

A recent Medical Group Management Association (MGMA) Stat poll asked healthcare leaders, “Will your practice add advanced practice providers (APPs) in 2021?” The majority (55%) said “yes,” compared with 45% who responded “no.” Read More ›

A diagnosis of breast cancer can cause stress and depression, especially in younger women. According to findings from a recent clinical trial, behavioral interventions may help decrease symptoms of depression and reduce anxiety, fatigue, and sleep disturbances in younger breast cancer survivors. Read More ›

The HER2-targeted bispecific investigational antibody zanidatamab, either as monotherapy or in combination with chemotherapy, has shown promising antitumor activity in an ongoing clinical trial of patients with HER2-expressing biliary tract cancer or gastroesophageal adenocarcinoma. Read More ›

Since 1980, the incidence of liver and intrahepatic bile duct cancer has more than tripled in the United States, whereas the death rates have more than doubled during this time. Read More ›

Induction chemotherapy leads to remission in many patients with acute myeloid leukemia (AML) aged ≥60 years; however, the disease relapses in most patients, resulting in poor overall survival (OS). Read More ›

Physicians often fail to perceive radiation-associated symptoms and the severity of those symptoms, according to the results of a large observational study that compared the reports of patients with breast cancer with physicians’ assessments of 4 common radiation-associated symptoms. Read More ›

Results of the SWOG S1007 RxPONDER clinical trial suggest that many postmenopausal women with early-stage hormone receptor (HR)-positive, human epidermal growth receptor 2 (HER2)-negative breast cancer, and 1 to 3 positive axillary lymph nodes may be able to avoid adjuvant chemotherapy. Read More ›

Final results from the phase 3 clinical trial ClarIDHy showed that ivosidenib (Tibsovo), a first-in-class oral inhibitor of isocitrate dehydrogenase 1 (IDH1) mutation, prolonged the median overall survival (OS) in patients with previously treated advanced cholangiocarcinoma (CCA) and IDH1 mutation. Read More ›

Enrollment in clinical trials is vital for the advancement of knowledge and improvement of patient outcomes, but few adults participate in cancer clinical trials. Read More ›

The combination of the investigational drug pevonedistat in combination with azacitidine injection (Vidaza) leads to longer event-free survival (EFS) and a higher complete response rate than azacitidine alone in patients with high-risk myelodysplastic syndromes (MDS), according to results from a phase 2, open-label, international clinical trial. Read More ›